Abstract: The present invention generally relates to Fab-based antibody-like binding proteins comprising three antigen-binding domains that specifically bind one or more target proteins, wherein the antibody domain interfaces are engineered so that they readily self-assemble. The disclosure also provides methods for making trispecific binding proteins and uses of such binding proteins.

Abstract: The present invention relates to bispecific antibodies that antagonize human PD-1 and agonize human CD137, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.

Abstract: Provided herein are proteins comprising T-cell receptor (TCR) constant domains with one or more stabilization mutations, nucleic acids encoding such proteins, and methods of making and using such proteins.

Abstract: The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.

Abstract: The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.

Abstract: The present invention relates to bispecific antibodies that antagonize human PD-1 and agonize human CD137, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.

Abstract: The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.

Abstract: The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (VH/VL) domain and the heavy chain-light chain constant (CH1/CL) domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.

Abstract: The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (VH/VL) domain and the heavy chain-light chain constant (CH/CL) domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.

Abstract: The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (VH/VL) domain and the heavy chain-light chain constant (CH1/CL] domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.

Abstract: IgG bispecific antibodies are provided that bind tumor necrosis factor alpha (TNF?) and the p19 subunit of interleukin-23 (IL-23p19) and are characterized as having high affinity and simultaneous neutralizing properties to both TNF? and IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, psoriasis, psoriatic arthritis, and Hidradenitis suppurativa.

Abstract: The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain light-chain variable (VH/VL) domain and the heavy chain-light chain constant (CH1/CL) domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.

Abstract: The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (VH/VL) domain and the heavy chain-light chain constant (CH1/CL] domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.

Abstract: The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (VH/VL) domain and the heavy chain-light chain constant (CH1/CL] domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.

Abstract: The invention provides antibodies with superior therapeutic efficacy and related methods of engineering such antibodies to increase their stability and resistance to proteases, e.g., in the digestive tract. Protease cleavage motifs are identified and subsequently modified to reduce or eliminate cleavage at that site. Methods of employing these orally deliverable antibodies as therapeutic compositions, particularly against gastrointestinal pathogens are also provided herein. In one aspect, the invention provides combinations of monoclonal antibodies, e.g., “synthetic polyclonals,” that work synergistically to neutralize bacterial toxins, particularly enteric bacterial toxins such as Clostridium difficile toxin A.